Download Free Medical Contraceptive Care for Women with HIV Infection and their Partners PowerPoint Presentation

Contraceptive Care for Women with HIV Infection and their Partners PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation titled ""Contraceptive Care for Women with HIV Infection and their Partners"" describes considerations for selecting appropriate contraceptive and compare options for women living with HIV, explains specific consideration related to hormonal contraception and antiretroviral treatment, and lists issue related to hormonal contraception and HIV progression, transmission or acquisition,

Tags : Contraceptive Care, HIV, Human Immunodeficiency Virus, HIV, infection, cells, immune system, AIDS, Acquired Immune Deficiency Syndrome, HIV Positive, Comorbidities, Comorbidity, hormonal contraception, antiretroviral treatment, Contraception, women, woman, pregnancy, STIs

Published on : Apr 23, 2021 | Views : 1761 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Contraceptive Care for Women with HIV Infection and their Partners Kimberly McClellan, MSN, WHNP-BC, CRNP Director Women's Health AIDS Care Group, Chester PA ksv23@drexel.edu
Slide 2-

Objectives Describe considerations for selecting appropriate contraceptive and compare options for women living with HIV Explain specific consideration related to hormonal contraception and antiretroviral treatment Identify issue related to hormonal contraception and HIV progression, transmission or acquisition
Slide 3-

Benefits of Contraception for HIV-Positive Women Prevents unintended pregnancy Half of all pregnancies in U.S. are unintended Allows women to plan a pregnancy that Is well timed Occurs in optimal health Minimizes risks for perinatal transmission
Slide 4-

Special Considerations Regarding HIV and Contraception Potential drug interaction with antiretrovirals (ARVs) Possible effects on HIV transmission Possible effects on HIV acquisition Possible effects on HIV progression
Slide 5-

Typical Effectiveness of Contraception HIV-positive women generally have the same options as uninfected women
Slide 6-

US Medical Eligibility Criteria for Contraceptive Use
Slide 7-

US Medical Eligibility Criteria: Categories
Slide 8-

Oral contraceptives Same medical criteria as for HIV-uninfected women if woman is NOT on ART Drug-drug interactions are possible between ARVs and hormonal contraceptives (HCs) HCs are metabolized by same pathways and cytochrome P450 enzymes as many PIs and NNRTIs These interactions can cause changes in the efficacy of the ARV or contraception ACOG (2010), Gynecologic care for women with human immunodeficiency virus. Practice Bulletin #117.
Slide 9-

Hormonal Contraception: Alternate Delivery Methods Combined Patch is a thin plastic square worn on body Releases estrogen and progestin through the skin Works by preventing ovulation Efficacy Limited research suggests may be more effective than COCs Decreased efficacy in women over 90 kg
Slide 10-

Hormonal Contraception: Alternate Delivery Methods Limited research suggests health risks and benefits are similar to COCs Side Effects Skin irritation or rash where patch is applied Changes in bleeding pattern Headaches Nausea Vomiting Breast tenderness Abdominal pain
Slide 11-

Hormonal Contraception: Alternate Delivery Methods Combined Vaginal Ring is placed into the vagina Releases estrogen and progestin Works by preventing ovulation Efficacy Limited research suggests may be more effective at preventing pregnancy than COCs
Slide 12-

Alternative Delivery Methods Limited research suggests risks and benefits similar to COCs Side effects Changes in bleeding pattern Headaches Nausea Breast tenderness Vaginitis Leukorrhea/increase in Lactobacillus
Slide 13-

Alternate Delivery Methods These delivery methods also vulnerable to drug interactions One small study found significant interaction between the estrogen and progestin hormones of the patch and lopinavir/ritonavir More research needed on these delivery methods
Slide 14-

DMPA Injectable (IM,SQ) progestin only contraception Given every 3 months Works by preventing ovulation Efficacy 97% effective as commonly used Over 99% effective when used as directed (3 pregnancies per 1000 women)
Slide 15-

Contraceptive Implants Thin rods or tubes containing a progestin hormone. Provide effective contraception for at least 3 yrs. Suppresses ovulation and changes cervical mucus. Menstrual irregularities in most users.
Slide 16-

Intrauterine devices (IUDs) No known drug interactions No increase in shedding of HIV 2 types Copper (Paragard) works for 10 years, may be associated with heavier menses, periods regular) Levonorgestrel IUD (Mirena) works for 5 years, reduces menstrual blood loss (is FDA-approved as a treatment for menorrhagia), periods scant and not regular
Slide 17-

Medical Eligibility Criteria for IUD* Category 2: A condition for which the advantages of using the method generally outweigh the theoretical or proven risks. Category 3: A condition for which the theoretical or proven risks usually outweigh the advantages of using the method. *Adapted from: U.S. medical eligibility criteria for contraceptive use.
Slide 18-

IUD and HIV Considerations No higher risk in HIV-positive women over uninfected women for Complications Infections IUD use not associated with increased risk for transmission to sex partners Women with IUD in place who develop AIDS should be monitored for pelvic infection
Slide 19-

Hormonal Contraception and NNRTI Interaction Table
Slide 20-

Hormonal Contraception and Ritonavir-boosted PI Table
Slide 21-

Hormonal Contraception and PIs without Ritonavir Table Adapted from: Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
Slide 22-

Hormonal Contraception and CCR5 antagonist/integrase inhibitor table Adapted from: Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
Slide 23-

Condoms Efficacy Pregnancy prevention as commonly used Male condom 85% Female condom 79% Pregnancy prevention when used correctly and consistently Male condom 98% Female condom 95% Male condom is 80-95% effective at preventing HIV transmission when used correctly and consistently
Slide 24-

Dual Contraceptive Use Condom use should be encouraged for women To prevent HIV/STI acquisition Condom use should be encouraged in HIV-positive women To prevent HIV transmission Prevent STI acquisition As an adjuvant to contraceptives Condoms alone have a failure rate of 15%-21% at preventing pregnancy
Slide 25-

Spermicides: Not recommended Spermicides are not recommended by CDC Disrupt cervical mucosa Potentially increase viral shedding Increase transmission of HIV to uninfected partners Diaphragms and cervical caps are not encouraged by the CDC due to concerns about their use with spermicides
Slide 26-

Female and Male Sterilization Contraceptive sterilization is the most widely used method of family planning Clients should be advised that sterilization should be considered permanent Male-vasectomy: Cutting/occluding both vas deferens 1st yr failure rate-0%-0.5% Female-sterilization Transabdominal Transcervical Tubal sterilization Occlusion method
Slide 27-

Hormonal Contraception and HIV Acquisition: WHO Technical Statement Most studies found no statistically significant association between oral contraception and HIV acquisition Evidence on injectable HC varied with some studies showing increases between 48% to 100% and other studies reporting no association Due to inconsistent data and limitations of the studies performed WHO rated the current evidence as low
Slide 28-

HIV Transmission and Hormonal Contraception: WHO Technical Statement Recent observational study found a 2-3 increase in HIV transmission in women using injectables over oral contraception Findings from studies assessing HC and genital HIV shedding are not consistent Studies assessing HC and viral load generally showed no negative effect WHO rates the evidence for HIV transmission and injectable use as low and HIV transmission and oral contraception as very low
Slide 29-

HIV Disease Progression and Hormonal Contraception: WHO Technical Statement None of the 10 observational studies conducted found a significant association between hormonal contraception and HIV progression One randomized controlled trial found an increased risk of progression for HC users compared to copper IUD users Due to flaws in this study --- high rates of method switching and loss to follow-up --- the evidence for HC and HIV progression is rated as low
Slide 30-

WHO Recommendations No restriction on the use of any hormonal contraceptive method for HIV-positive women or women at high risk for HIV infection Critical importance must be placed on the consistent and correct use of condoms for the prevention of HIV acquisition or transmission Most concern is focused on the evidence of HIV acquisition and DMPA because a causal relationship is neither established nor ruled out Voluntary use of contraception by HIV positive women who wish to prevent pregnancy continues to be an important PMTCT strategy
Slide 31-

Thank you! Contact the FXB Center with questions or comments, or for a copy of the slide set: Mary Jo Hoyt hoyt@umdnj.edu